


Bupropion found to not improve sexual desire for female cancer survivors

December 10 2021



Credit: Unsplash/CC0 Public Domain

Despite preliminary supporting evidence that the dopaminergic agent bupropion might improve sexual desire for female cancer survivors, the NRG Oncology CC004 clinical trial determined that bupropion did not improve outcomes when compared to a placebo. Though the results of this trial were negative, this study supports the urgent need to find



effective treatment solutions for the large population of women who are concerned about side effects to their sexual desire following their cancer therapy. These results were published in the *Journal of Clinical Oncology*.

NRG-CC004 compared two dose-levels of extended-release <u>bupropion</u> in <u>postmenopausal women</u> who were diagnosed with breast or gynecologic <u>cancer</u> and completed their <u>cancer treatment</u>, but who had low baseline <u>sexual desire</u> scores (

Citation: Bupropion found to not improve sexual desire for female cancer survivors (2021, December 10) retrieved 27 April 2024 from https://medicalxpress.com/news/2021-12-bupropion-sexual-desire-female-cancer.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.